Bank Of New York Mellon Corp I Mab Transaction History

Bank Of New York Mellon Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$4.01 - $12.34 $6,399 - $19,694	1,596 Added 7.72%	22,261 $89,000
Q2 2022 Aug 15, 2022	SELL	$8.27 - $18.43 $251,118 - $559,626	-30,365 Reduced 59.5%	20,665 $234,000
Q1 2022 May 11, 2022	SELL	$12.54 - $46.93 $229,682 - $859,569	-18,316 Reduced 26.41%	51,030 $829,000
Q4 2021 Feb 11, 2022	BUY	$45.28 - $74.5 $1.86 Million - $3.06 Million	41,056 Added 145.13%	69,346 $3.29 Million
Q2 2021 Aug 11, 2021	BUY	$47.86 - $83.95 $1.35 Million - $2.37 Million	28,290 New	28,290 $2.37 Million

16M

11.9K

3.5K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $131M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.